Equity Profile

WAT

Waters Corporation

Health CareLife Sciences Tools & Services$40.6B

Jul29Wed

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Waters Corporation (WAT) operates in the health care sector, specifically in life sciences tools and services. The company is known for its analytical instruments and software used in laboratories, which are crucial for drug development and quality control in various industries.

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and financial health, which investors closely monitor.

$3.01

Revenue

Revenue figures provide insights into the company's sales performance and market demand for its products.

$1.6B

Wall Street expectations, options signals, track record, and call prep available with Pro.

WAT Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+5.04%

Avg Stock Reaction

+2.29%

Last Quarter Recap

In Q1-2026, Waters Corporation reported an EPS of $2.70, significantly beating the estimate of $2.31, which led to a 13.54% increase in stock price the following day. However, revenue figures were not disclosed.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Waters Corporation to report strong earnings this quarter, with a consensus EPS of $3.01. The market is optimistic about the company's ability to continue its growth trajectory.

Bull Case

If Waters exceeds EPS expectations and demonstrates strong revenue growth, it could signal robust demand for its products, leading to a positive stock reaction.

Bear Case

Conversely, if the company fails to meet earnings expectations or provides weak guidance, it could raise concerns about future growth, potentially leading to a decline in stock price.

Key Metrics to Watch

EPS

$3.01

Earnings per share is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue

$1.6B

Revenue figures provide insights into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Waters Corporation's EPS exceed the consensus estimate of $3.01?

A beat on EPS could reinforce investor confidence and lead to a positive stock reaction, as seen in previous quarters.

What guidance will management provide regarding future revenue growth?

Management's outlook on revenue growth will be critical for assessing the company's ability to sustain its performance and meet market expectations.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the impact of recent product launches and increased demand in the life sciences sector, which could lead to stronger-than-expected earnings.

Supporting Evidence

Waters has consistently beaten EPS estimates in the past, suggesting potential for continued strong performance.

The options market is pricing a smaller move than historical averages, indicating potential for a larger reaction.

Recent trends in the life sciences market suggest increasing investment in analytical tools, which could benefit Waters.

Key Risk

If the company reports lower-than-expected revenue growth, it could challenge the optimistic outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Waters can maintain its growth momentum after a strong Q1 performance, and the upcoming earnings report will provide clarity.

Bull Confirmed If

An EPS of $3.04 or higher, along with strong revenue growth, would confirm the bull case.

Bear Confirmed If

An EPS below $2.98 or weak revenue guidance would support the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±4.4%

Historical Avg

±8.3%

Pricing cheap

The options market is pricing in a modest move of approximately 4.4% around the earnings announcement, indicating uncertainty but not extreme volatility.

Options are pricing ±4.4% while WAT has averaged ±8.3% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.4%

30d HV

57.9%

Calls (13K)P/C Ratio: 0.45Puts (1K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Waters beats expectations, history suggests the stock could rise by about 2.29% on the day, confirming strong demand.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction, reflecting cautious sentiment among investors.

Miss

In the event of a miss, the stock could decline, with historical patterns indicating a potential drop around 2.69%.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected impact on sales.
2Management's commentary on market demand trends in the life sciences sector.
3Insights into operational efficiencies and cost management strategies.
4Guidance on revenue expectations for the next quarter and beyond.
5Any commentary on competitive pressures and market share.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

PreviewView

Jul27

ARLPBMO

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and financial health, which investors closely monitor.

$3.01

Revenue

Revenue figures provide insights into the company's sales performance and market demand for its products.

$1.6B

Wall Street expectations, options signals, track record, and call prep available with Pro.

WAT Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+5.04%

Avg Stock Reaction

+2.29%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Waters Corporation to report strong earnings this quarter, with a consensus EPS of $3.01. The market is optimistic about the company's ability to continue its growth trajectory.

Bull Case

If Waters exceeds EPS expectations and demonstrates strong revenue growth, it could signal robust demand for its products, leading to a positive stock reaction.

Bear Case

Conversely, if the company fails to meet earnings expectations or provides weak guidance, it could raise concerns about future growth, potentially leading to a decline in stock price.

Key Metrics to Watch

EPS

$3.01

Earnings per share is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue

$1.6B

Revenue figures provide insights into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Waters Corporation's EPS exceed the consensus estimate of $3.01?

A beat on EPS could reinforce investor confidence and lead to a positive stock reaction, as seen in previous quarters.

What guidance will management provide regarding future revenue growth?

Management's outlook on revenue growth will be critical for assessing the company's ability to sustain its performance and meet market expectations.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the impact of recent product launches and increased demand in the life sciences sector, which could lead to stronger-than-expected earnings.

Supporting Evidence

Waters has consistently beaten EPS estimates in the past, suggesting potential for continued strong performance.

The options market is pricing a smaller move than historical averages, indicating potential for a larger reaction.

Recent trends in the life sciences market suggest increasing investment in analytical tools, which could benefit Waters.

Key Risk

If the company reports lower-than-expected revenue growth, it could challenge the optimistic outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Waters can maintain its growth momentum after a strong Q1 performance, and the upcoming earnings report will provide clarity.

Bull Confirmed If

An EPS of $3.04 or higher, along with strong revenue growth, would confirm the bull case.

Bear Confirmed If

An EPS below $2.98 or weak revenue guidance would support the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±4.4%

Historical Avg

±8.3%

Pricing cheap

The options market is pricing in a modest move of approximately 4.4% around the earnings announcement, indicating uncertainty but not extreme volatility.

Options are pricing ±4.4% while WAT has averaged ±8.3% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

0.4%

30d HV

57.9%

Calls (13K)P/C Ratio: 0.45Puts (1K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Waters beats expectations, history suggests the stock could rise by about 2.29% on the day, confirming strong demand.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction, reflecting cautious sentiment among investors.

Miss

In the event of a miss, the stock could decline, with historical patterns indicating a potential drop around 2.69%.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected impact on sales.
2Management's commentary on market demand trends in the life sciences sector.
3Insights into operational efficiencies and cost management strategies.
4Guidance on revenue expectations for the next quarter and beyond.
5Any commentary on competitive pressures and market share.